Company Overview - MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for endocrine and metabolic disorders [3] - The company is advancing a pipeline that includes canvuparatide for chronic hypoparathyroidism in Phase 2 development, MBX 1416 for post-bariatric hypoglycemia in Phase 1 development, and an obesity portfolio including MBX 4291 with an IND filing anticipated in Q2 2025 [3] Upcoming Events - Kent Hawryluk, President and CEO of MBX Biosciences, will present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025, from 10:30 a.m. to 11:00 a.m. ET in Boston, MA [1] - The company will also participate in the Jefferies Biotech on the Beach Summit on March 12, 2025, with a format of 1x1 meetings in Miami Beach, FL [2] - Presentation webcasts will be accessible on the investors section of the MBX Biosciences website, with replays available approximately two hours after the events [2]

Core Insights - Microbix Biosystems Inc. reported Q1 fiscal 2025 revenues of $6.0 million, reflecting a 40% year-over-year increase in recurring sales from diagnostic-test related ingredients and devices [1][2][3] Financial Performance - Total revenue for Q1 was $6,044,002, with antigen revenues at $4,266,758, marking a significant 118% increase from the previous year [3] - QAPs revenues were $1,626,980, down 28% from last year due to reduced activity from test manufacturers [3] - Net income for the quarter was $0.9 million, compared to $2.5 million in Q1 2024, which included non-recurring Kinlytic licensing revenues [6][8] - Gross margin percentage for Q1 was 62%, down from 74% in the prior year, but improved from 49% when excluding Kinlytic revenues [4] Operating Expenses - Operating expenses decreased by 23% compared to Q1 2024, primarily due to lower consulting fees related to the Kinlytic licensing agreement [5] Cash Flow and Ratios - Cash provided by operating activities was $792,702, down from $1,338,952 in Q1 2024 [6][9] - Current ratio at the end of Q1 was 6.62, and debt-to-equity ratio was 0.36, both affected by share repurchases [7][9] Corporate Outlook - The company aims to continue driving sales growth across all business lines and expects meaningful year-over-year revenue growth for the full fiscal year 2025 [10]

Company Overview - Microbix Biosystems Inc. is a life sciences innovator, manufacturer, and exporter, focusing on proprietary biological products for human health [4] - The company has over 120 skilled employees and aims for revenues of C$ 2.0 million or more per month [4] - Microbix specializes in critical ingredients and devices for the global diagnostics industry, including antigens for immunoassays and laboratory quality assessment products (QAPs™) [4] Upcoming Financial Results - Microbix is set to file its financial statements and management disclosure for Q1 2025, which ended on December 31, 2024, prior to trading on February 13, 2025 [1] - A webinar discussion regarding the Q1 2025 results will be held at 11:00 AM ET on the same day, featuring the CEO, CFO, and COO [1] Webinar Participation - Investors and shareholders can participate in the webinar by registering through a provided link, and it will also be live-streamed on YouTube [2] - A replay of the webinar will be available on Adelaide Capital's YouTube channel [3] Product and Market Focus - Microbix's antigens are utilized in antibody tests by approximately 100 diagnostics manufacturers, while QAPs are sold to clinical lab accreditation organizations and clinical labs [4] - The company's QAPs are available in over 30 countries, supported by a network of international distributors [4] - Microbix also develops proprietary products such as Kinlytic® urokinase, a biologic thrombolytic drug, and reagents for molecular diagnostic testing [5]

Core Viewpoint - Microbix Biosystems Inc. has raised C$ 2.4 million through the partial exercise of expiring share purchase warrants, which will be utilized to enhance product development, manufacturing capacity, and operational efficiency [1][3]. Group 1: Capital Raise and Warrant Details - The company received C$ 2.4 million from the exercise of 6,703,314 out of 8,881,564 remaining 2020 Warrants, representing 75.5% of the unexercised warrants [2][4]. - The 2020 Warrants were originally issued in January 2020 at an exercise price of C$ 0.36 with a five-year term [2]. Group 2: Use of Proceeds - The additional capital will be directed towards broadening product development capabilities, expanding manufacturing capacity, and improving operational efficiency [3]. - A portion of the funds may also be allocated to debt reduction or share repurchases under the company's Normal-Course Issuer Bid [3]. Group 3: Financial Position - Following the warrant exercises, Microbix has a current ratio of over 7.0 times and a debt-to-equity ratio of approximately 0.30, indicating strong financial health [5]. - The company's cash and equivalents balance exceeds C$ 15 million after the warrant exercises [4]. Group 4: Company Overview - Microbix Biosystems specializes in creating proprietary biological products for human health, targeting sales of C$ 2.0 million or more per month [6]. - The company manufactures critical ingredients for the global diagnostics industry, including antigens for immunoassays and laboratory quality assessment products (QAPs™) [6]. - Microbix is ISO 9001 & 13485 accredited and registered with U.S. FDA, Australian TGA, and Health Canada, ensuring compliance with international standards [6][7].

Company Overview - MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for endocrine and metabolic disorders [3] - The company is based in Carmel, Indiana and utilizes its proprietary PEP™ platform to advance its pipeline of candidates [3] Pipeline Development - The lead product candidate, MBX 2109, is in Phase 2 development for chronic hypoparathyroidism (HP) [3] - MBX 1416 is in Phase 1 development for post-bariatric hypoglycemia (PBH) [3] - The obesity portfolio includes MBX 4291 and multiple discovery and pre-clinical candidates aimed at treating obesity [3] Upcoming Investor Conferences - Kent Hawryluk, President and CEO, will present at the Guggenheim SMID Cap Biotechnology Conference on February 5, 2025, from 2:00 - 2:25 p.m. EST in New York, NY [1] - He will also participate in the BIO CEO & Investor Conference on February 10, 2025, from 11:00 a.m. – 12:00 p.m. EST in New York, NY [2] - Additionally, he will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference virtually on February 11, 2025, from 8:40 - 9:10 a.m. EST [2]

Core Insights - Microbix Biosystems Inc. and American Proficiency Institute have launched a pilot proficiency testing program to validate molecular diagnostic assays for detecting the H5N1 strain of the Influenza A virus, which poses a potential pandemic threat [1][2] Group 1: Company Overview - Microbix Biosystems Inc. is a life sciences innovator focused on creating proprietary biological products for human health, with over 100 employees and monthly sales targeting C$ 2.0 million or more [4] - The company manufactures and exports critical ingredients and devices for the global diagnostics industry, including antigens for immunoassays and laboratory quality assessment products (QAPs™) [5] - Microbix's QAPs are sold to clinical lab accreditation organizations, diagnostics companies, and clinical labs, and are available in over 30 countries [5] Group 2: Industry Context - The H5N1 strain of the Influenza A virus is a novel strain that has shown the ability to infect birds, cattle, and humans, raising concerns about its potential to cause a pandemic [1] - The proficiency testing program aims to ensure that clinical laboratories can reliably detect H5N1 Flu using established molecular diagnostic tests, which include both regulator-approved assays and laboratory-developed tests [1] - API's proficiency testing programs are internationally accredited and support over 20,000 clinical laboratories, enhancing the accuracy and efficiency of clinical laboratory testing [3]

Core Insights - Microbix Biosystems Inc. is expanding its platform capabilities to produce a wider range of recombinant antigens, enhancing its market share as a supplier to immunoassay manufacturers [1][3]. Group 1: Company Overview - Microbix has over three decades of experience as a leading producer of purified and inactivated antigens, supplying over 100 international manufacturers of immunoassays [2]. - The company reported sales of native antigens totaling C$ 13.8 million in fiscal 2024, marking a 44% increase from the previous year [2]. - Microbix is ISO 9001 & 13485 accredited and registered with U.S. FDA, Australian TGA, and Health Canada, ensuring compliance with international standards [6]. Group 2: Expansion Plans - The company plans to invest approximately C$ 0.5 million per year to enhance its internal capabilities in synthetic biology for the production of recombinant antigens [4]. - By the end of 2025, this initiative is expected to broaden the total addressable market by offering a wider range of infectious-disease antigens at various price points [5]. - The recombinant antigens will also serve as ingredients for Microbix's QAPs test-controls, providing immediate internal validation for external customers [5]. Group 3: Market Position and Strategy - Microbix aims to leverage its expertise in recombinant technologies to produce antigens that can offer price advantages over native antigens without compromising assay performance [3]. - The company’s strategic focus on recombinant antigens is anticipated to significantly grow sales in this important segment of its business [3].

Phase 1 results support proceeding to Phase 2 in patients with post-bariatric hypoglycemia (PBH), which is expected to begin in 2H 2025 Phase 1 trial in healthy volunteers showed MBX 1416 was generally well-tolerated with a favorable safety profile Pharmacokinetic results demonstrated sustained dose-dependent exposure and support once-weekly dosing Company to host conference call to discuss results today at 8:30 am ET CARMEL, Ind., Jan. 07, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a cli ...

Full-Year Revenues of $25.4 million and Net Income of $3.5 millionMISSISSAUGA, Canada, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, reports results for its fiscal year and fourth quarter ended September 30, 2024 (“2024” and “Q4”) with record revenues, reflective of ongoing progress to increase sales from its diagnostic-test related ingredients and devices businesses and that resulted in material net inc ...

Company Overview - MBX Biosciences is a clinical-stage biopharmaceutical company focused on developing precision peptide therapies for endocrine and metabolic disorders using its proprietary PEP™ platform [3] - The company is advancing a pipeline of novel candidates targeting endocrine and metabolic disorders with clinically validated targets, established regulatory endpoints, significant unmet medical needs, and large market opportunities [3] - Key pipeline includes MBX 2109 (Phase 2 for chronic hypoparathyroidism), MBX 1416 (Phase 1 for post-bariatric hypoglycemia), and MBX 4291 (obesity portfolio) [3] Upcoming Events - The company's President and CEO, Kent Hawryluk, will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025, at 2:15 PM Pacific Time [1] - MBX Biosciences will participate in 1-on-1 investor meetings during the conference [1] - A live webcast of the presentation will be available on the company's investor website, with a replay accessible approximately two hours post-event and archived for 30 days [2]